These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 21625416)

  • 1. Development of oral immunomodulatory agents in the management of multiple sclerosis.
    Nicholas R; Giannetti P; Alsanousi A; Friede T; Muraro PA
    Drug Des Devel Ther; 2011; 5():255-74. PubMed ID: 21625416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
    Gold R
    CNS Drugs; 2011 Jan; 25(1):37-52. PubMed ID: 21128693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune therapy of multiple sclerosis--future strategies.
    Meuth SG; Göbel K; Wiendl H
    Curr Pharm Des; 2012; 18(29):4489-97. PubMed ID: 22612746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C; Ruggieri S
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM; Rainka MM; Patel MJ; Gengo FM
    Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.
    Melzer N; Meuth SG
    Clin Exp Immunol; 2014 Mar; 175(3):359-72. PubMed ID: 24032475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging multiple sclerosis oral therapies.
    Rammohan KW; Shoemaker J
    Neurology; 2010 Jan; 74 Suppl 1():S47-53. PubMed ID: 20038763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral laquinimod treatment in multiple sclerosis.
    Fernández O
    Neurologia; 2011 Mar; 26(2):111-7. PubMed ID: 21163185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying agents in multiple sclerosis.
    O'Connor PW; Oh J
    Handb Clin Neurol; 2014; 122():465-501. PubMed ID: 24507532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging oral therapies in multiple sclerosis.
    Conway D; Cohen JA
    Curr Neurol Neurosci Rep; 2010 Sep; 10(5):381-8. PubMed ID: 20549393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.
    Thöne J; Ellrichmann G
    Drug Healthc Patient Saf; 2013; 5():37-47. PubMed ID: 23459383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriflunomide for oral therapy in multiple sclerosis.
    Papadopoulou A; Kappos L; Sprenger T
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):617-28. PubMed ID: 23234322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
    Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC
    Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.